New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kazuhiko Uchiyama, Tomohisa Takagi, Yasunori Iwamoto, Norihiko Kondo, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Osamu Handa, Takeshi Ishikawa, Hiroaki Yasuda, Junichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares